VisionSys AI Inc
VSADrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rebamipide 2% ophthalmic suspension | Phase 3 | Dry Eye Syndrome | - | - |
Frequently asked questions
What is in VisionSys AI Inc's drug pipeline?→
CatalystAlert tracks 1 drug candidate in VisionSys AI Inc's (VSA) pipeline across Phase 3. Its lead program is Rebamipide 2% ophthalmic suspension (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VisionSys AI Inc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for VisionSys AI Inc (VSA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VSA biotech catalysts?→
Add VSA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VisionSys AI Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.